Dr. Boyle is currently the William J. von Liebig Professor of Biomedical Sciences in the Department of Biology at Juniata College in Huntingdon, Pennsylvania. Dr. Boyle received his B.Sc. (with honors) in biochemistry from the University of Glasgow, Glasgow, Scotland and his Ph.D. from the Chester Beatty Research Institute, Belmont Surrey, UK. Following his graduate education, Dr. Boyle joined the National Cancer Institute as a Visiting Fellow in the Humoral Immunity section of the Laboratory of Immunobiology. Dr. Boyle left the National Institutes of Health in 1981 to take an academic appointment as Associate Professor of Microbiology in the Department of Immunology and Medical Microbiology, College of Medicine at the University of Florida, becoming a full Professor in 1985. In 1998, Dr. Boyle took the faculty position as Professor of Immunology in the Department of Medical Microbiology and Immunology at the Medical College of Ohio, Toledo, OH. He also served as Executive Director of the NW Ohio Life Sciences Incubator and Director of the Pathogenesis and Immunology program of the Medical College of Ohio Cancer Initiative. Dr. Boyle has also served on numerous editorial boards for scientific journals as editor and reviewer. He has also been a member of various National Institutes of Health (NIH), National Science Foundation (NSF) and American Heart Association (AHA) grant study sections. Dr. Boyle is nationally and internationally recognized for his research in the areas of bacterial FC-binding proteins, wound healing, immunochemistry, and molecular pathogenesis having published 190 scientific articles in these areas and having been the recipient of extramurially funded grants from NIH, NSF, ACS, AHA and industry. Dr. Boyle holds 13 US patents on discoveries resulting from his studies. Dr. Boyle is also the founder and President of Gator Microbiologicals, Inc. (now Receptor Pro) a privately held biotechnology company that specializes in the commercialization of bacterial FC-binding proteins and other important bacterial antigens.